Tarlatamab plus anti–PD‐L1 as first‐line maintenance for ES‐SCLC demonstrates promising results

Cancer 2026 Open access

Read full text

Authors: Leah Lawrence

DOI: 10.1002/cncr.70179

Cited by: 3

References: 2

Fields of Study & Subjects

Lung Cancer Research Studies PARP inhibition in cancer therapy Cancer therapeutics and mechanisms

References 2